ストックスクリーナーアプリを入手
0.8144
1.42%
0.0114
プレマーケット:
.81
-0.0044
-0.54%
Revelation Biosciences Inc (REVB) 最新ニュース
Revelation Biosciences, Inc. Completes the GMP Manufacture of Gemini Clinical Drug Supply - BioSpace
Revelation Bio Achieves Key Manufacturing Milestone for Kidney Disease Drug Trial | REVB Stock News - StockTitan
United Therapeutics (UTHR) Stock Dips Amid Broader Biotech Indus - GuruFocus.com
Allergic Rhinitis Treatment Market Size in the 7MM is expected to Grow by 2034 | DelveInsight - Barchart
REVB: Good Expense Control as Company Prepares for Trials - Research Tree
Pre-market Movers: REVB, CDIO, SMLR, DWTX... - RTTNews
Why Revelation Biosciences Shares Are Trading Higher By Around 49%; Here Are 20 Stocks Moving Premarket - Benzinga
REVB Results Set Stage for Future Growth - Yahoo Finance
Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2024 - sharewise
Revelation Biosciences Inc expected to post a loss of $2.29 a shareEarnings Preview - XM
Revelation Bio Q3 Loss Narrows to $2.2M, Secures $3.8M from Warrants Amid Cash Decline | REVB Stock News - StockTitan
Revelation Biosciences Inc (REVB) Quarterly 10-Q Report - Quartzy
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.14% - MSN
Revelation Biosciences faces Nasdaq delisting over noncompliance - Investing.com India
United States shares lower at close of trade; Dow Jones Industrial Average down 0.43% - MSN
ROTH to Host 3rd Annual Healthcare Opportunities Conference on October 9 in New York City - The Manila Times
A better buy-in window may exist right now for Revelation Biosciences Inc (REVB) - SETE News
Revelation Biosciences Inc Inc. (REVB) Price Performance: A Guide to Technical Indicators - The InvestChronicle
Farallon Capital Management LLC Boosts Stake in Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat
Revolution Medicines added to Analyst Focus List at JPMorgan - TipRanks
Revelation Biosciences’ Gemini Induces Dose Dependent Significant Increases in IL-10 - Morningstar
Revolution Medicines, Inc. (NASDAQ:RVMD) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Revolution Medicines (NASDAQ:RVMD) Trading Down 6.1% - MarketBeat
A stock that deserves closer examination: Revelation Biosciences Inc (REVB) - US Post News
Revance Therapeutics Shares Fall on Crown Labs Deal Delay - MarketWatch
Financial Fitness Check: Examining Revelation Biosciences Inc (REVB)’s Key Ratios - The Dwinnex
Revance Therapeutics plunges as Crown Labs tender offer delayed amid Teoxane dispute - Seeking Alpha
Revolve Group (NYSE:RVLV) Reaches New 1-Year High at $25.96 - Defense World
Revelation Biosciences stock hits 52-week low at $0.78 - Investing.com India
Revelation Biosciences stock hits 52-week low at $0.78 By Investing.com - Investing.com Australia
Revolution Medicines executive sells over $500k in company stock By Investing.com - Investing.com Canada
Revolution Medicines COO sells over $191k in company stock By Investing.com - Investing.com Canada
Revolution Medicines CFO sells over $99k in company stock - Investing.com India
Revolution Medicines executive sells over $200k in company stock - Investing.com
Revolution Medicines general counsel sells shares worth over $64k By Investing.com - Investing.com UK
Renovaro faces Nasdaq delisting over share price woes By Investing.com - Investing.com Australia
The growth track for Revolution Medicines Inc (RVMD) has changed recently - SETE News
Crown Labs tender offer for Revance delayed, expect deal to be completedanalyst - MSN
Revelation Pharma Announces Revelation Wholesale, an Extension of Its National Compounding Network - PR Newswire
455,099 Shares in Revolution Medicines, Inc. (NASDAQ:RVMD) Bought by Sofinnova Investments Inc. - MarketBeat
Revolve Group (NYSE:RVLV) Trading Down 5.2% - MarketBeat
Revance Therapeutics falls as Crown Labs didn't start tender offer by deadline (update) - Seeking Alpha
RVLV stock soars to 52-week high, touches $24.67 - Investing.com
Financial Metrics Check: Revelation Biosciences Inc (REVB)’s Ratios for Trailing Twelve Months - The Dwinnex
United States shares higher at close of trade; Dow Jones Industrial Average up 0.14% - MSN
Revelation Biosciences announces warrant exercise and inducement - Investing.com India
Revelation Biosciences Inc. Announces Exercise of Warrants for $3.8 Million in Gross Proceeds - Manchestertimes
Stock Performance Spotlight: Revelation Biosciences Inc (REVB) Ends the Day at 1.25, Down by -40.19 - The Dwinnex
Nasdaq Down Over 200 Points; Williams-Sonoma Shares Tumble After Q2 Results - Benzinga
Gold Down Over 1%; US Initial Jobless Claims Increase - Benzinga
Revelation Biosciences Inc [REVB] Stock trading around $2.09 per share: What’s Next? - The DBT News
Adversity is less terrifying than hope: Revelation Biosciences Inc (REVB) - SETE News
Microsoft seeks to win over new players at gamer gathering - Yahoo Finance UK
Cytek® Biosciences Achieves ISO 13485 Certification at San Diego Reagent Manufacturing Facility - Yahoo Finance
Keysight stock rising on Q3 earnings beat, upbeat guidance - Yahoo Finance
Uniti Group Inc. to Participate at the Citi 2024 Global TMT Conference - Yahoo Finance
Shein sues Temu alleging copyright infringement and fraud - Yahoo! Voices
Yacht insurance provider OMAC is hull carrier for sunken yacht in Sicily, sources say - Yahoo News UK
Ford delays BlueOval City truck launch date - Yahoo! Voices
RNC’s Latest Fundraising Is a Sign of How Much Trump Is Struggling - Yahoo! Voices
What is REVB’s price-to-sales ratio telling us about the company’s value? - US Post News
CONSOL Energy Inc. and Arch Resources merge to create Core Natural Resources - Yahoo News
Nvidia has a Buy rating from 66 analysts. Here's why - Yahoo Finance
US Stocks Higher; Target Posts Upbeat Earnings - Benzinga
REVB’s Market Whiplash: -93.09% YTD Decline, -35.90% Plunge in 30 Days - The InvestChronicle
3.66%
1.11%
大文字化:
|
ボリューム (24 時間):